Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.
Dymock, B.W., Barril, X., Brough, P.A., Cansfield, J.E., Massey, A., McDonald, E., Hubbard, R.E., Surgenor, A., Roughley, S.D., Webb, P., Workman, P., Wright, L., Drysdale, M.J.(2005) J Med Chem 48: 4212-4215
- PubMed: 15974572 
- DOI: https://doi.org/10.1021/jm050355z
- Primary Citation of Related Structures:  
2BSM, 2BT0 - PubMed Abstract: 
The crystal structure of a previously reported screening hit 1 (CCT018159) bound to the N terminal domain of molecular chaperone Hsp90 has been used to design 5-amide analogues. These exhibit enhanced potency against the target in binding and functional assays with accompanying appropriate cellular pharmacodynamic changes. Compound 11 (VER-49009) compares favorably with the clinically evaluated 17-AAG.
Organizational Affiliation: 
Vernalis Ltd., Granta Park, Great Abington, Cambridge, UK.